Effect | Decrease |
Trial Design | Non-controlled trial |
Trial Length | n/a |
Number of Subjects | 227 |
Sex | n/a |
60mg Harpagoside daily for 8 weeks (brand name Doloteffin) provided some relief to patients when assessed by WOMAC, Modified HAQ, and Arhus index; more efficacy was noted in persons worse off with pain and disease progression